Management of EGFR-mutated non-small-cell lung cancer: practical implications from a clinical and pathology perspective (original) (raw)

Navigating the "No Man's Land" of TKI-Failed EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC): A Review

Neoplasia (New York, N.Y.), 2018

Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)

Pharmaceuticals, 2020

Clinical efficacy of EGFR-TKIs in combination with chemotherapy in patients with advanced non-small cell lung cancer harboring EGFR mutations

mingyang liu

Journal of thoracic disease, 2016

View PDFchevron_right

The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients

Anna Rachiglio

Cancers

View PDFchevron_right

Targeting the EGFR T790M mutation in non-small-cell lung cancer

Amelia D'Alessio

Expert opinion on therapeutic targets, 2016

View PDFchevron_right

Making progress in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer by surpassing resistance: third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs)

Giannis Mountzios

Annals of Translational Medicine

View PDFchevron_right

Management of EGFR mutated nonsmall cell lung carcinoma patients

Bogdan D. Grigoriu

The European respiratory journal, 2015

View PDFchevron_right

Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies

Giannis Mountzios

Cancers

View PDFchevron_right

Adjuvant TKI therapy in resected EGFR-mutant non-small-cell lung cancer—ready for prime time?

Surein Arulananda

Translational Lung Cancer Research, 2020

View PDFchevron_right

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Current Status and Future Perspectives in the Development of Novel Irreversible Inhibitors for the Treatment of Mutant Non-small Cell Lung Cancer

maricla galetti

Current Pharmaceutical Design, 2012

View PDFchevron_right

EGFR-tyrosine kinase mutations in non-small cell lung cancer-based responsiveness to anti-cancer therapy

Editor VISNAV

Visnav, 2021

View PDFchevron_right

Efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy for advanced EGFR-mutated non-small cell lung cancer: systematic review and meta-analysis

Elena Dragioti

DOAJ (DOAJ: Directory of Open Access Journals), 2021

View PDFchevron_right

Treatment in EGFR-mutated non-small cell lung cancer: how to block the receptor and overcome resistance mechanisms

Giuseppe Lo Russo

Tumori, 2017

View PDFchevron_right

Multidisciplinary and real life data: practical management of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC)

Francesco Martella

Journal of Thoracic Disease

View PDFchevron_right

Drug delivery and drug resistance: EGFR-tyrosine kinase inhibitors in non-small cell lung cancer

Godefridus J Peters

View PDFchevron_right

Does the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor differ according to the type of EGFR mutation in non-small cell lung cancer?

Jin-Hyuk Choi

The Korean journal of internal medicine, 2017

View PDFchevron_right

Overall Survival Analysis and Characterization of an EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) Population

Venceslau Hespanhol

Archivos de bronconeumologia, 2017

View PDFchevron_right

Beyond EGFR and ALK: targeting rare mutations in advanced non-small cell lung cancer

Giannis Mountzios

Annals of Translational Medicine

View PDFchevron_right

EGFR tyrosine kinase mutation testing in the treatment of non-small-cell lung cancer

Denis Soulières

Current oncology (Toronto, Ont.), 2012

View PDFchevron_right

Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs)

Sacha Rothschild

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2016

View PDFchevron_right

Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and New Therapeutic Perspectives in Non Small Cell Lung Cancer

Laura Bonanno

Current Drug Targets, 2011

View PDFchevron_right

Uncommon EGFR mutations in lung adenocarcinomas: Clinical features and response to tyrosine kinase inhibitors

Emmanuel Watkin

Annals of Oncology, 2018

View PDFchevron_right

Identifying activating mutations in the EGFR gene: prognostic and therapeutic implications in non-small cell lung cancer

Edoardo Vattimo

Jornal brasileiro de pneumologia : publicaça̋o oficial da Sociedade Brasileira de Pneumologia e Tisilogia, 2015

View PDFchevron_right

REVIEW Open Access EGFR inhibition in non-small cell lung cancer: current evidence and future directions

guang zhaohui

View PDFchevron_right

Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond

Marc Ladanyi

Modern Pathology, 2008

View PDFchevron_right

Drug resistance to EGFR tyrosine kinase inhibitors for non-small cell lung cancer

Junichi Soh

Acta medica Okayama, 2014

View PDFchevron_right

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: A new era begins

Jordi Remon, E. Dalmau

2014

View PDFchevron_right

Acquired EGFR-resistant mutations in non–small cell lung cancer (NSCLC)

luis raez

Journal of Clinical Oncology, 2022

View PDFchevron_right

EGFR_Mutation_and_Tyrosine_Kinase_Inhibitors_(TKI)_in_Non Small_Cell_Lung_Cancer_An_Overview.pdf

SSR Institute of International Journal of Life Sciences

View PDFchevron_right

Uncommon EGFR mutations in advanced non-small cell lung cancer

Frances Shepherd

Lung cancer (Amsterdam, Netherlands), 2017

View PDFchevron_right

EGFR Mutation Positive Stage IV Non-Small-Cell Lung Cancer: Treatment Beyond Progression

Yolande Lievens

Frontiers in Oncology, 2014

View PDFchevron_right

Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer

Savvas Papadopoulos

Journal of Experimental & Clinical Cancer Research, 2012

View PDFchevron_right

Antitumoral Activity of Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harbouring Rare Epidermal Growth Factor Receptor Mutations

Emmanuel De Laere, Elke Boone

Molecular Diagnosis & Therapy, 2015

View PDFchevron_right

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

Maria Arcila

Clinical Cancer Research, 2013

View PDFchevron_right

CLINICAL CASE STUDY EGFR mutation positive stage IV non-small-cell lung cancer: treatment beyond progression

devi efrina

View PDFchevron_right

Management of EGFR-mutated non-small-cell lung cancer: practical implications from a clinical and pathology perspective (original) (raw)

Related papers